REQUEST A DEMO
Total
USD $0.00
Search more companies

Futuresynthesis Sp. z o.o. (Poland)

Main Activities: Other Basic Organic Chemical Manufacturing
Full name: Futuresynthesis Sp. z o.o. Profile Updated: May 22, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Polish Download a sample report

FUTUREsynthesis offers a precision RNA mass marker for short RNA molecules and distributes ELK Biotechnology products in Poland. The company also provides synthesis of nucleic acids with various modifications and fluorescent labeling, as well as fluorescent colorants and sampling mixtures of nucleic acids for molecular biology-based analysis and diagnosis. FUTUREsynthesis is the only company with Polish capital offering large-scale synthetic oligonucleotides of RNA and DNA series.

Headquarters
Ul. Rubiez 46/B
Poznan; Wielkopolskie; Postal Code: 61-612

Contact Details: Purchase the Futuresynthesis Sp. z o.o. report to view the information.

Website: http://www.futuresynthesis.pl

Basic Information
Total Employees:
Purchase the Futuresynthesis Sp. z o.o. report to view the information.
Outstanding Shares:
Purchase the Futuresynthesis Sp. z o.o. report to view the information.
Registered Capital:
Purchase the Futuresynthesis Sp. z o.o. report to view the information.
Incorporation Date:
April 12, 2011
Key Executives
Purchase this report to view the information.
President
Ownership Details
Purchase this report to view the information.
98%
Company Performance
Financial values in the chart are available after Futuresynthesis Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
-42.17%
Total operating revenue
4.27%
Operating profit (EBIT)
-52.69%
EBITDA
-12.14%
Net Profit (Loss) for the Period
-50.66%
Total assets
-8.3%
Total equity
4.52%
Operating Profit Margin (ROS)
-6.53%
Net Profit Margin
-4.97%
Return on Equity (ROE)
-20.13%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?